

**Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting**

*600 East Broad Street – 7th Floor Conference Rooms
Richmond, Virginia 23219*

Thursday, October 16, 2014 - 10:00 a.m.

Welcome and Comments from DMAS' Director

Cynthia B. Jones

Call to Order

Tim Jennings, Pharm.D., Chairman

Drug Utilization Review (DUR) Board Update

Avtar Dhillon, M.D., DMAS DUR Board

Magellan Health Update

Debbie Moody, R.Ph., Clinical Manager

Approval of Minutes From April, 24th 2014 Meeting

P&T Committee Members

PDL Management

P&T Committee Members

- **Potential New Therapeutic Class Review (PDL Category)**
 - Anti-Allergens, Oral (*Respiratory*)
 - Anticonvulsants (*Central Nervous System*)
 - Antidepressants, Other & SSRI (*Central Nervous System*)
 - Antipsychotics (*Central Nervous System*)
 - Antihypertensives, Sympatholytics (*Cardiac Medications*)
 - Epinephrine, Self-Injected (*Respiratory*)
 - Glucocorticoids, Oral (*Endocrine & Metabolic Agents*)
 - Steroids, Topical (*Dermatologic Agents*)

- **PDL Phase II – New Drug Review**
 - Acne Agents, Topical (Neuac™)
 - Analgesics, Narcotic Long Narcotics (Xartemis™ XR, hydromorphone ER, morphine ER)
 - Androgenic Agents (Vogelxo™ gel & pump, testosterone topical gel, transdermal gel & pump)
 - Antivirals, Oral (Sitavig® buccal tablets)
 - Bone Resorption Suppression And Related Agents (raloxifene, risedronate)
 - Hypoglycemics, Incretin Mimetics/Enhancers (Tanzeum™)
 - Hypoglycemics, SGLT2 (Jardiance®, Invokamet™)
 - Opiate Dependence Treatments (Bunavail™)
 - Platelet Aggregation Inhibitors (Zontivity™)
 - Quinolones (ciprofloxacin solution)
 - Self Administered Drugs for Rheumatoid/Psoriatic Arthritis (Otezla®, Otrexup™, Rasuvo™)

- **PDL Phase I – Annual Review**
 - Antibiotic-Anti-Infective**
 - Antibiotics, Inhaled
 - Antibiotics, Vaginal

 - Antivirals**
 - Hepatitis C

 - Blood Modifiers**
 - Hereditary Angioedema (HAE)

 - Cardiac Medications**
 - Angiotensin-Converting Enzyme Inhibitors (*includes combination products*)
 - Angiotensin II Receptor Antagonists (*includes combination products*)
 - Beta Blockers (*includes combination products*)
 - Calcium Channel Blockers (*includes dihydropyridine and non-dihydropyridine agents*)
 - Direct Renin Inhibitors

Cardiac Medications (cont.)

- Lipotropics (*includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agent, Fibric Acid derivatives, HMG CoA Reductase Inhibitors-Statins Niacin derivatives, Niacin/Statin combinations, Microsomal Triglyceride Transfer Protein Inhibitor, Oligonucleotide Inhibitors and Omega 3 agents*)
- Pulmonary Hypertension Agents (*Endothelin-1 agents, PDE-5 Inhibitors; Prostacyclin analogues, Prostacyclin Vasodilator, Soluble Guanylate Cyclase Stimulators*)

Central Nervous System

- Alzheimer's Agents
- Sedative Hypnotics
- Other Sedative Hypnotics

Endocrine & Metabolic Agents

- Growth Hormones
- Progestins for Cachexia

Gastrointestinal

- Antiemetic/Antivertigo Agents
- Bile Salts
- H.pylori Treatments
- Histamine-2 Receptor Antagonists (H-2RA)
- Irritable Bowel Syndrome
- Proton Pump Inhibitors
- Ulcerative Colitis (oral and rectal)

Genitourinary

- BPH Agents (*includes Alpha Blockers, Androgen Hormone Inhibitors and Phosphodiesterase (PDE) 5 Inhibitor for BPH treatment*)
- Phosphate Binders
- Bladder Relaxants

Immunological Agents

- Topical Immunomodulators (atopic dermatitis)

Ophthalmics

- Antibiotic/Steroid Combinations
- Antibiotics
- Anti-Inflammatory Agents(*includes Ophthalmic NSAIDS & Corticosteroids*)
- Allergic Conjunctivitis (*includes Ophthalmic Antihistamines & Mast Cell Stabilizers*)
- Glaucoma Agents (*includes Alpha-2 Adrenergic, Beta-blockers, Carbonic Anhydrase Inhibitors, Prostaglandin Inhibitors*)

Respiratory

- Antihistamines – Second Generation (LSAs)
- Beta Adrenergics – (*includes short acting, long acting, nebulized and combinations*)
- COPD (*includes Anticholinergics, Bronchodilators and Phosphodiesterase 4 (PDE4) Inhibitors*)
- Corticosteroids (*includes nebulized solutions, metered dose inhalers and combinations*)
- Legend Cough & Cold Agents
- Intranasal Antihistamines and Corticosteroids
- Leukotriene Formation Inhibitors and Modifiers

Confidential Meeting (Pricing Information Discussion)

**P&T Committee, DMAS & PS Staff
Pursuant to 42 USC §1396r-8**

PDL Recommendations and Vote

P&T Committee Members

Criteria Discussion of Phase II New Drugs*

P&T Committee Members

Criteria Discussion of PDL Phase I Drug Classes*

P&T Committee Members

Next Meeting – April 16, 2015

Tim Jennings, Pharm. D., Chairman

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on **only** the drug classes in Phase I which are scheduled for review at the October meeting and new drugs in PDL Phase II listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase I Annual Reviews – October 2013 to present
- New Drugs in PDL Phase I or II Drug Classes – October 2012 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send requested information to pdlinput@dmas.virginia.gov and dfmoody@magellanhealth.com by 5 p.m. EST on **Friday, September 19, 2014.**

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov by 5 p.m. EST on **September 19, 2014.**